BioSpace News Archive

Ancora Heart, Inc. , a company developing a novel therapy to address heart failure, today announced U.S. Food and Drug Administration (FDA) approval of its Investigational Device Exemption (IDE) application for the CorCinch-HF pivotal study, which is designed to evaluate the safety and e

Camino Pharma, LLC, a biotech company focused on finding cures for cancer and brain disorders, announced today that its co-founder and CSO, Reto Gadient , Ph.D., has been awarded a two-year, $920K SBIR grant by the National Institute of Mental Health (NI

Ajinomoto Bio-Pharma Services (“Aji Bio-Pharma”), a leading provider of biopharmaceutical contract development and manufacturing services, is pleased to announce the launch of AJILITY™, a flexible and agile drug product manufacturing platform, designed to advance vaccines and therapies to market by minimizing time to production.

Unique Combination of Proprietary Technologies for Innovative Tumor Processing Workflow Expected to Accelerate Cancer R&D with Expanded IDs of Critical Disease State Biomarkers with Higher Precision and Speed

Surgical implant maker Xenco Medical has announced the nationwide launch of the first injection-molded titanium foam spinal implants pre-attached to disposable, composite polymer instruments, the CancelleX porous titanium lumbar interbodies. Inspired by cancellous bone, Xenco Medical’s CancelleX lumbar interbodies feature interconnected porosity throughout each implant and break new ground in the application of injection molding

CES Innovation Awards Winner NextMind Opens Public Preorders for Wearable Brain-Sensing DevKit

Initiation follows positive results from cohort 6 of phase 1b COSMIC-021 trial – – CONTACT-02 is the second of three phase 3 pivotal trials that are part of a clinical collaboration with Roche – ALAMEDA, Calif.--( BUSINESS WIRE )-- Exelixis, Inc. (NASDAQ: EXEL) today announced the initiation of CONTACT-02, a global phase 3 pivotal trial of cabozantinib (CABOMETYX ® ) in combination with atezolizumab (TECENTRIQ ® ) in patients with met

DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today that as part of the annual reconstitution of the Russell stock indexes, DermTech has been selected to be added to the Russell 2000 ® Index effective June 26, 2020. “We are pleased to have earned our inclusion in the Russell 2000 ® Index, one of the most widely cited perfo

Twist Bioscience Corporation (Nasdaq: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the availability of the Twist Respiratory Virus Research Panel , a robust next-generation sequencing (NGS) approach to detecting a wide rang

At least one dose in each study demonstrated a measurable treatment effect in 100% of subjects at 4 weeks, with median duration of 27 weeks in forehead lines and 24 weeks in crow’s feet - - DaxibotulinumtoxinA for Injection was well tolerated across all doses in both indications - NEWARK, Calif.--( BUSINESS WIRE )-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, i